GSK961081

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2015
01220132015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
To investigate the pharmacokinetics of inhaled batefenterol (BAT) and fluticasone furoate (FF) given alone or in combination via… (More)
Is this relevant?
2015
2015
Through application of our multivalent approach to drug discovery we previously reported the first discovery of dual pharmacology… (More)
Is this relevant?
2015
2015
GSK961081 (batefenterol) is a novel bifunctional molecule composed of a muscarinic antagonist and a β2-agonist. The aims of this… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2014
2014
OBJECTIVE To investigate the pharmacokinetics and pharmacodynamics of inhaled GSK961081 and fluticasone propionate (FP) given… (More)
  • figure 2
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
2014
2014
PURPOSE The objective of this study was to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
GSK961081 is a bifunctional molecule demonstrating both muscarinic antagonist and β-agonist activities. This was a 4-week… (More)
Is this relevant?
2013
2013
BACKGROUND There are few data on the bronchodilatory effects of adding short-acting bronchodilators (SABA) to maintenance, long… (More)
Is this relevant?